Gold prices steady ahead of Fed decision; weekly weakness noted
LONDON - PureTech Health plc (Nasdaq:PRTC, LSE: PRTC) has issued ordinary shares to six non-executive directors following the vesting of previously granted restricted share units (RSUs), according to a company statement released Friday.
The RSUs, which were awarded on June 26, 2024, and November 8, 2024, under the company’s Performance Share Plan, vested in full on June 13, 2025, with the directors receiving their shares on July 1, 2025.
Five directors - Raju Kucherlapati, John LaMattina, Robert Langer, Kiran Mazumdar-Shaw, and Sharon Barber-Lui - each received 59,202 ordinary shares, while Michele Holcomb received 50,000 shares. All shares were issued at a price of £0.01 per share.
Following the share issuance, PureTech’s total issued ordinary share capital stands at 257,927,489 shares, with 17,234,267 shares held in treasury by the company.
PureTech Health is a clinical-stage biotherapeutics company focused on developing new classes of medicine for patients with various diseases. The transaction details were disclosed in accordance with Article 19 of the EU Market Abuse Regulation, as stated in the press release.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.